Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41375-021-01264-8 http://scihub22266oqcxt.onion/10.1038/s41375-021-01264-8 34002026!8127467!34002026     free     free     free Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Leukemia 2021 ; 35 (6): 1661-1670 Nephropedia Template TP {{tp|p=34002026|t=2021. Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19) |pdf=|usr=}}{{34002026}} gab.com Text Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19) JO: Leukemia http://www.kidney.de/pget.php?&tw=1&pmid=34002026 #FOAvip We performed a meta-analysis to determine safety and efficacy of tocilizumab in persons with coronavirus disease-2019 (COVID-19). We searched PubMed, Web of Science and Medline using Boolean operators for studies with the terms coronavirus OR COVID-19 OR 2019-nCoV OR SARS-CoV-2 AND tocilizumab. Review Manager 5.4 was used to analyze data and the modified Newcastle-Ottawa and Jadad scales for quality assessment. We identified 32 studies in 11,487 subjects including three randomized trials and 29 cohort studies with a comparator cohort, including historical controls (N = 5), a matched cohort (N = 12), or concurrent controls (N = 12). Overall, tocilizumab decreased risk of death (Relative Risk [RR] = 0.74; 95% confidence interval [CI], 0.59, 0.93; P = 0.008; I(2) = 80%) but not of surrogate endpoints including ICU admission (RR = 1.40 [0.64,3.06]; P = 0.4; I(2) = 88%), invasive mechanical ventilation (RR = 0.83 [0.57,1.22]; P = 0.34; I(2) = 65%) or secondary infections (RR = 1.30 [0.97,1.74]; P = 0.08; I(2) = 65%) and increased interval of hospitalization of subjects discharged alive(mean difference [MD] = 2 days [<1, 4 days]; P = 0.006; I(2) = 0). RRs of death in studies with historical controls (RR = 0.28 [0.16,0.49; P < 0.001]; I(2) = 62%) or a matched cohort (RR = 0.68 [0.53, 0.87]; P = 0.002; I(2) = 42%) were decreased. In contrast, RRs of death in studies with a concurrent control (RR = 1.10 [0.77, 1.56]; P = 0.60; I(2) = 85%) or randomized (RR = 1.18 [0.57,2.44]; P = 0.66; I(2) = 0) were not decreased. A reduced risk of death was not confirmed in our analyses which questions safety and efficacy of tocilizumab in persons with COVID-19. Twit Text FOAVip Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19) ????Leukemia http://www.kidney.de/pget.php?&tw=1&pmid=34002026 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34002026 #FOAvip English Wikipedia <ref>{{Cite pmid|34002026}}</ref> Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19) #MMPMID34002026 Chen CX; Hu F; Wei J; Yuan LT; Wen TM; Gale RP; Liang Y Leukemia 2021[Jun]; 35 (6): 1661-1670 PMID34002026show ga We performed a meta-analysis to determine safety and efficacy of tocilizumab in persons with coronavirus disease-2019 (COVID-19). We searched PubMed, Web of Science and Medline using Boolean operators for studies with the terms coronavirus OR COVID-19 OR 2019-nCoV OR SARS-CoV-2 AND tocilizumab. Review Manager 5.4 was used to analyze data and the modified Newcastle-Ottawa and Jadad scales for quality assessment. We identified 32 studies in 11,487 subjects including three randomized trials and 29 cohort studies with a comparator cohort, including historical controls (N = 5), a matched cohort (N = 12), or concurrent controls (N = 12). Overall, tocilizumab decreased risk of death (Relative Risk [RR] = 0.74; 95% confidence interval [CI], 0.59, 0.93; P = 0.008; I(2) = 80%) but not of surrogate endpoints including ICU admission (RR = 1.40 [0.64,3.06]; P = 0.4; I(2) = 88%), invasive mechanical ventilation (RR = 0.83 [0.57,1.22]; P = 0.34; I(2) = 65%) or secondary infections (RR = 1.30 [0.97,1.74]; P = 0.08; I(2) = 65%) and increased interval of hospitalization of subjects discharged alive(mean difference [MD] = 2 days [<1, 4 days]; P = 0.006; I(2) = 0). RRs of death in studies with historical controls (RR = 0.28 [0.16,0.49; P < 0.001]; I(2) = 62%) or a matched cohort (RR = 0.68 [0.53, 0.87]; P = 0.002; I(2) = 42%) were decreased. In contrast, RRs of death in studies with a concurrent control (RR = 1.10 [0.77, 1.56]; P = 0.60; I(2) = 85%) or randomized (RR = 1.18 [0.57,2.44]; P = 0.66; I(2) = 0) were not decreased. A reduced risk of death was not confirmed in our analyses which questions safety and efficacy of tocilizumab in persons with COVID-19. |*COVID-19 Drug Treatment[MESH] |Antibodies, Monoclonal, Humanized/adverse effects/*therapeutic use[MESH] |COVID-19/mortality[MESH] |Hospitalization[MESH] |Humans[MESH] |Intensive Care Units[MESH] |SARS-CoV-2/*drug effects[MESH]Systematic review and meta-analysis of tocilizumab in persons with cor(epmc).pdf DeepDyve Pubget Overpricing